Zura Bio Limited (NASDAQ:ZURA - Get Free Report) Director Parvinder Thiara sold 1,001,633 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Zura Bio Price Performance
Zura Bio stock opened at $3.00 on Thursday. The firm has a fifty day simple moving average of $4.12 and a two-hundred day simple moving average of $4.03. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $6.35.
Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). As a group, research analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.
Analyst Ratings Changes
ZURA has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a research report on Friday, October 18th. Leerink Partnrs upgraded shares of Zura Bio to a "strong-buy" rating in a research report on Monday, November 4th. HC Wainwright reissued a "neutral" rating and issued a $5.00 price target on shares of Zura Bio in a report on Monday, November 18th. Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They set an "outperform" rating and a $15.00 price objective for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zura Bio has an average rating of "Buy" and an average target price of $15.80.
This Crypto Is Set to Explode in December
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Read Our Latest Stock Analysis on Zura Bio
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Zura Bio during the 3rd quarter valued at $46,000. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the second quarter worth about $43,000. SG Americas Securities LLC purchased a new position in Zura Bio during the 3rd quarter valued at about $62,000. Renaissance Technologies LLC raised its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Zura Bio in the 3rd quarter worth approximately $71,000. Institutional investors own 61.14% of the company's stock.
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
